MKI-3 is a selective microtubule-associated serine/threonine kinase-like ( MASTL ) inhibitor with an IC 50 of 5.72 nM and a K d of 1.89 nM. MKI-3 disrupts the MASTL-ENSA-Aurora A signaling axis. MKI-3 induces chromosomal instability, mitotic catastrophe and apoptosis ( apoptosis ) in cancer cells. MKI-3 is applicable to research related to triple-negative breast cancer .
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > MASTL | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Aurora Kinase | Products > Signaling Pathways > PARP
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.